Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 4
- 主要终点
- Efficacy of a L-MOD against controls receiving supportive care in ICU.
研究概览
简要总结
Current treatment recommendations are based on very limited evidence and reliant on the deployment of pharmacological strategies of doubtful efficacy, high toxicity, and near universal shortages of supply. On a global scale, there is a desperate need for readily available therapeutic options to safely and cost effectively target the hyper-inflammatory state in ICU patients based on management of severe COVID-19 (evidence of acute respiratory distress syndrome). The study team proposes to use slow low-efficiency daily dialysis to provide an extracorporeal circuit to target this cytokine storm using immunomodulation of neutrophils with a novel leucocyte modulatory device (L-MOD) to generate an anti-inflammatory phenotype, but without depletion of circulating factors.
详细描述
The coronavirus disease 2019 (COVID-19) is a novel virus that was first reported in December 2019 from Wuhan, China. So far, over 8,000,000 cases have been reported around the globe with >400,000 reported deaths overwhelming hospitals and constraining resources. Death is mainly due to severe acute respiratory syndrome (SARS), requiring mechanical ventilation; however, many hospitals do not have sufficient equipment (i.e. ventilators) to meet the requirements. It had been suggested that severe SARS-related injury may have be related to an excessive reaction of the host's immune system, and a dysregulation of pro-inflammatory cytokines called cytokine storm syndrome. This is characterized by a hyper-inflammatory state leading to fulminant multi-organ failure and elevated cytokine levels. There is a critical and imminent need to identify effective treatments to reduce mortality.
The study team proposes to use slow low-efficiency daily dialysis (SLEDD) to provide an extracorporeal circuit to target this cytokine storm using immunomodulation of neutrophils with a novel leukocyte modulatory device (L-MOD) to generate an anti-inflammatory phenotype, without depletion of circulating factors.
This is a single center, prospective, randomized controlled pilot study in the Critical Care Trauma Centre at Victoria Hospital and Critical Care at University Hospital, London, Ontario. Critical Care at University Hospital is comprised of two units, the Medical-Surgical ICU and the Cardiac Surgical Recovery Unit. The study team will randomize patients requiring ICU admission of COVID-19 into one of two groups; either to standard of care for severe COVID-19 infection or in the active treatment group (standard supportive care + treatment with leukocyte modulation (using L-MOD)), on 1:1, basis. They will know what treatment group they are randomized to.
The study team will use block randomization to randomize the patients into one of these two groups. A computer algorithm is used to generate the randomization sequence in blocks of four (two for standard of care and two for active treatment). This is used to make sure that equal numbers of people get allocated to each arm of the study and that the allocation is equal throughout the lifespan of the trial.
Slow low-efficiency daily dialysis will be performed twice, for approximately 12 hours, 2 days in a row. Due to the nature of the intervention, it is not possible to blind neither the patient nor study team members to the treatment group the patient gets randomized to, with the exception of study team members analyzing the data who will be blinded to the patients' treatment group. Additionally, the study uses robust objective measurements that will be unaffected by the patients' awareness of the group they have been randomized to.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 18 years
- •High clinical suspicion of COVID-19 from the opinion of both infectious disease specialist (s) and the ICU team
- •Evidence of acute respiratory distress syndrome requiring admission to the Critical Care Trauma Centre Medical Surgical ICU, or the Cardiac Surgical Recovery Unit
- •Vasopressor support
排除标准
- •Unconfirmed COVID-19
- •Chronic immune depression
- •Contra-indications to regional citrate anticoagulation
结局指标
主要结局
Efficacy of a L-MOD against controls receiving supportive care in ICU.
时间窗: Through dialysis, on average of 12 hours, two days in a row
Efficacy will be evaluated by reduction of vasopressor support (converted to norepinephrine dose equivalents) compared to control group.
次要结局
- Myocardial damage(From date of randomization until the date of ICU discharge up to 2 months)
- Mortality(From date of randomization until the date of death from any cause, whichever came first, assessed up to 2 months)
- Renal recovery(From date of randomization until the date of ICU discharge up to 2 months)
- Markers of Inflammation(Through dialysis, on average of 12 hours, two days in a row and again after day 4 and no later than day 7 in the ICU)
- Leukocytes and Macrophages(Through dialysis, on average of 12 hours, two days in a row and again after day 4 and no later than day 7 in the ICU)
- Hospital Discharge(From date of randomization until the date of hospital discharge or death from any cause, whichever came first, assessed up to 2 months)
- Leukocyte Monitoring(Through dialysis, on average of 12 hours, two days in a row and again on day 5 in the ICU)
- Sequential Organ Failure Assessment (SOFA) Score(From date of randomization until the date of ICU discharge or death from any cause, whichever came first, assessed up to 1 months)
- Intubation length(From date of randomization until the date of ICU discharge up to 2 months)
研究者
Chris McIntyre
Principal Investigator
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's